mRNA Levels Of Lipogenic Enzymes Research Articles

Role of Jumonji‐C Histone Demethylase in the Development of Hepatocellular Carcinoma

Reprogramming in lipid metabolism has received increasing recognition as a hallmark of cancer cells. In cancer cells, large demands of lipids were required to meet excessive synthesis of membranes, energy production and activation of intracellular signaling pathways during cell proliferation. To meet these demands, cancer cells express increased levels of lipogenic enzymes responsible for FAs synthesis, which is a target of crucial transcriptional regulator, sterol regulatory element binding protein 1c (SREBP1c). SREBP1c is a well‐known master transcription factor for de novo lipogenesis and is found frequently increased in many human cancers. However, the molecular mechanisms involved in the regulation of SREBP1c remain incompletely understood. In this study, we uncover the role of jumonji‐C histone demethylase (JHDM) as a repressor of SREBP1c, thereby preventing lipogenesis and proliferation of hepatocellular carcinoma (HCC) cells. JHDM directly interacts with SREBP1c at basic helix‐loop‐helix domain of SREBP1c and plant homeodomain of JHDM, promoting proteasomal degradation of SREBP1c protein. In addition, knockdown of JHDM stimulates mRNA levels of lipogenic enzymes and induces lipogenesis in HCC cells. However, JHDM‐loss‐induced lipogenesis is recovered by SREBP1c knockdown, implying that SREBP1c is crucial for the effects of JHDM toward lipogenesis. In contrast, ectopic expression of JHDM shows protective effects on oleic acid‐induced lipid accumulation in HCC cells. We also found that JHDM knockdown using si‐RNAs promotes mRNA expressions of cell cycle regulators, accompanied with enhanced cell growth, colony formation and spheroid formation. However, the effects of JHDM knockdown which promote HCC proliferation are reversed by knockdown of SREBP1c. In accordance with these data, JHDM overexpression represses cell growth in HCC cells, indicating that JHDM acts as a tumor suppressor by inhibiting SREBP1c‐mediated lipogenesis and cell cycle regulation. Overall, our findings suggest that JHDM serves as a molecular bridge between lipid metabolism and cancer development through regulation of SREBP1c and thus JHDM could be a therapeutic target in defense against HCC.Support or Funding InformationThis work was supported by grants from the National Research Foundation of Korea (2016R1A2B4013377, 2018R1A2B6007241, 2019R1A2C2083886).

Physiological effects of an oil rich in γ-linolenic acid on hepatic fatty acid oxidation and serum lipid levels in genetically hyperlipidemic mice.

We investigated the physiological activity of an oil rich in γ-linolenic acid of evening primrose origin (containing 42.6% γ-linolenic acid) affecting hepatic fatty acid metabolism, and serum lipid levels in genetically hyperlipidemic mice deficient in apolipoprotein E expression. Male apolipoprotein E-deficient mice (BALB/c.KOR/StmSlc-Apoeshl) were fed experimental diets containing 100 g/kg of palm oil (saturated fat), safflower oil (rich in linoleic acid), γ-linolenic acid oil (rich in γ-linolenic acid), or fat mixtures composed of safflower and γ-linolenic acid oils (65:35 and 30:70, w/w) for 20 days. γ-Linolenic acid oil, compared with palm and safflower oils, strongly and dose-dependently increased the activity and mRNA levels of hepatic fatty acid oxidation enzymes. In general, safflower and γ-linolenic acid oils, compared with palm oil, reduced the activity and mRNA levels of lipogenic enzymes. However, these oils were equivalent in reducing the parameters of lipogenesis, excluding malic enzyme and pyruvate kinase. The diets containing safflower and γ-linolenic acid oils, compared with the palm oil diet, significantly decreased serum triacylglycerol and cholesterol levels. The decreases were greater with γ-linolenic acid oil than with safflower oil. γ-Linolenic acid oil exerted strong serum lipid-lowering effects in apolipoprotein E-deficient mice apparently through the changes in hepatic fatty acid metabolism.

Spironolactone in Combination with α-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation.

Administration of the diuretic, spironolactone (SR), can inhibit chronic liver diseases. We determined the effects of SR alone or in combination with the antioxidant α-glycosyl isoquercitrin (AGIQ) on hyperlipidemia- and steatosis-related precancerous lesions in high-fat diet (HFD)-fed rats subjected to a two-stage hepatocarcinogenesis model. Rats were fed with control basal diet or HFD, which was administered with SR alone or in combination with an antioxidant AGIQ in drinking water. An HFD increased body weight, intra-abdominal fat (adipose) tissue weight, and plasma lipids, which were reduced by coadministration of SR and AGIQ. SR and AGIQ coadministration also reduced hepatic steatosis and preneoplastic glutathione S-transferase placental form-positive foci, in association with decrease in NADPH oxidase (NOX) subunit p22phox-positive cells and an increase in active-caspase-3-positive cells in the foci. Hepatic gene expression analysis revealed that the coadministration of SR and AGIQ altered mRNA levels of lipogenic enzymes ( Scd1 and Fasn), antioxidant-related enzymes ( Catalase), NOX component ( P67phox), and anti-inflammatory transcriptional factor ( Pparg). Our results indicated that SR in combination with AGIQ had the potential of suppressing hyperlipidemia- and steatosis-related early hepatocarcinogenesis through the reduced expression of NOX subunits.

Intestinal microbiota and lipid metabolism responses in the common carp (Cyprinus carpio L.) following copper exposure

The present study was conducted to determine the effects of waterborne copper exposure on the lipid metabolism and intestinal microbiota of juvenile common carp (Cyprinus carpio L.). Common carp were exposed to four waterborne copper (Cu) concentrations (0 (control), 0.07 (low), 0.14 (medium), and 0.28 (high) mg Cu/L) for 8 weeks. Exposure to a high concentration of Cu had a negative effect on growth indices (weight gain rate (WGR) and specific growth rate (SGR)). The biochemical indices measured in serum (low-density lipoprotein (LDL) and triglycerides (TGs)) were significantly affected by exposure to medium concentration levels of Cu. The mRNA levels of lipogenic enzymes (acetyl-CoA carboxylase 1 (ACC-1) and fatty acid synthase (FAS)) and sterol-regulator element-binding protein-1 (SREBP-1) in liver tissue and tight binding protein genes (ZO-1 and occludin) in intestinal epithelial tissue were significantly downregulated in the 0.14 and 0.28 mg/L Cu treatment groups, accompanied by upregulated mRNA levels of lipolysis enzymes (lipoprotein lipase (LPL) and carnitine palmitoyl transferase 1 (CPT-1)) in the liver. The data also showed that the composition of intestinal microbiota was changed following Cu exposure and could alter the α-diversity and β-diversity. The abundances of few putative short-chain fatty acid (SCFA)-producing bacteria, including Allobaculum, Blautia, Coprococcus, Faecalibacterium, Roseburia, and Ruminococcus, decreased significantly. More specifically, Roseburia sequences were positively associated with lipogenic enzymes, total protein (TP), and TGs and negatively associated with lipolysis enzymes. Other sequences related to probiotics (Lactobacillus, Bacillus and Akkermansia) were also found to decrease, accompanied by an increase in sequences related to pathogens (Pseudomonas and Acinetobacter). To the best of our knowledge, the present study provides the first evidence that waterborne, chronic Cu exposure can disturb the composition of intestinal microbiota related to lipid metabolism and immunity in freshwater fish, thereby increasing the risk of pathogen invasion.

Comparison of Anti-obesity Effects of Spirit Vinegar and Natural Fermented Vinegar Products on the Differentiation of 3T3-L1 Cells and Obese Rats Fed a High-fat Diet

This study aimed to compare the effects of spirit vinegar and four types of natural fermented vinegar products (apple vinegar, brown rice vinegar, lemon vinegar, and balsamic vinegar) on the differentiation of 3T3-L1 cells and obesity in rats fed a high-fat diet (HFD). Vinegar inhibited the accumulation of lipid droplets during the differentiation of 3T3-L1 cells. Body weight gains, visceral fat pad weights, serum leptin and triglyceride levels, and hepatic lipogenic enzyme mRNA levels were significantly decreased in the HF-vinegar administered groups compared with those in the HF group. Furthermore, oral administration of vinegars significantly reduced the occurrence of fatty liver deposits and steatosis, and inhibited the HF diet-induced increase in adipocyte size. The anti-obesity and lipid-lowering effects were slightly greater in the HF-natural fermented vinegar groups than in the HF-spirit vinegar group. Apple vinegar had the strongest anti-obesity effects in 3T3-L1 cells and obese rats compared with the other tested vinegars. These findings indicated that vinegar administration may have potential for improving some obesity-related parameters in 3T3-L1 cells and obese rats.

Triglyceride synthesis in hepatocytes isolated from rats fed a low-protein diet is enhanced independently of upregulation of insulin signaling

It is known that protein malnutrition develops fatty liver in rats. However, the mechanisms by which protein malnutrition enhances lipid accumulation in the liver are not fully understood. Our previous studies have demonstrated that protein malnutrition upregulates insulin signaling with an increase in TG levels in rat livers. Here, we examined whether the upregulated insulin signaling contributes to an enhancement of TG accumulation under protein malnutrition. As it is difficult to analyze insulin-induced hepatic TG synthesis in vivo, the isolated hepatocytes derived from rats fed a low-protein diet were used. The hepatocytes were isolated from rats fed a 15% casein diet (15C) as a control diet or a 5% casein diet (5C) as a low-protein diet and then treated with insulin. As shown in vivo, insulin signaling was upregulated in isolated hepatocytes from 5C-fed rats (5C hepatocytes). However, the insulin-induced increase in the mRNA levels of lipogenic enzymes, including acetyl-CoA carboxylase 1 (ACC1) and fatty acid synthase (FAS), was similar in both groups. The amounts of TG synthesized from both glucose and palmitate, as well as ACC1 and FAS protein levels, were increased at the basal state in 5C hepatocytes, but were not further increased by insulin. These results indicate that TG synthesis via both de novo fatty acid synthesis and esterification is enhanced in 5C hepatocytes, which is independent of the upregulation of insulin signaling.

Fish oil prevents excessive accumulation of subcutaneous fat caused by an adverse effect of pioglitazone treatment and positively changes adipocytes in KK mice.

Pioglitazone, a thiazolidinedione (TZD), is widely used as an insulin sensitizer in the treatment of type 2 diabetes. However, body weight gain is frequently observed in TZD-treated patients. Fish oil improves lipid metabolism dysfunction and obesity. In this study, we demonstrated suppression of body weight gain in response to pioglitazone administration by combination therapy of pioglitazone and fish oil in type 2 diabetic KK mice. Male KK mice were fed experimental diets for 8 weeks. In safflower oil (SO), safflower oil/low-dose pioglitazone (S/PL), and safflower oil/high-dose pioglitazone (S/PH) diets, 20% of calories were provided by safflower oil containing 0%, 0.006%, or 0.012% (wt/wt) pioglitazone, respectively. In fish oil (FO), fish oil/low-dose pioglitazone (F/PL), and fish oil/high-dose pioglitazone (F/PH) diets, 20% of calories were provided by a mixture of fish oil and safflower oil. Increased body weight and subcutaneous fat mass were observed in the S/PL and S/PH groups; however, diets containing fish oil were found to ameliorate these changes. Hepatic mRNA levels of lipogenic enzymes were significantly decreased in fish oil-fed groups. These findings demonstrate that the combination of pioglitazone and fish oil decreases subcutaneous fat accumulation, ameliorating pioglitazone-induced body weight gain, through fish oil-mediated inhibition of hepatic de novo lipogenesis.

CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice.

Lymphocytes have a critical role in visceral adipose tissue (AT) inflammation. The CD28 costimulatory molecule is required for lymphocyte activation and for the development of a functional regulatory T cells (Tregs) compartment; however, its role during obesity is unknown. During diet-induced obesity, we investigated the effects of selective interference with CD28 signaling using knockout mice (Cd28KO) and a CTLA4-Ig fusion protein inhibiting CD28-B7 interactions. Cd28 deficiency decreased pathogenic T cells and Treg content within AT without changing the macrophages number. Cd28KO epididymal but not subcutaneous fat was characterized by enlarged adipocytes, reduced levels of inflammatory cytokines and increased Glut4, adiponectin and lipogenic enzyme mRNA levels. This was associated with reduced inflammation, fat accumulation and enhanced glucose metabolism in liver. Weight gain and fasting glucose tolerance were not affected. CTLA4-Ig injections reduced the number of T cells in epididymal AT (epiAT) but not the inflammatory cytokines levels and failed to improve liver fat accumulation. Deletion of CD28 creates a new pro/anti-inflammatory balance in epiAT and liver and exerts a protective effect against hepatic steatosis.

Metformin ameliorates diet‐induced hepatic steatosis and inflammation without altering adipose phenotype (37.1)

Non‐alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis and inflammation, and is closely associated with obesity. We examined the effects of metformin on hepatic steatosis and inflammation to elucidate the possible protective mechanisms of metformin actions. Wild‐type C57BL/6J mice were fed a high‐fat diet (HFD) for 12 weeks and treated with metformin (150 mg/kg/d) orally for the last four weeks of HFD feeding. We found that metformin improved glucose tolerance and insulin sensitivity, and decreased liver weight and hepatic steatosis but not adiposity of HFD‐fed mice compared with controls. Additionally, metformin increased the phosphorylation of liver AMP‐activated protein kinase (AMP) and decreased the phosphorylation of liver c‐Jun N‐terminal kinase 1 (JNK1) and the mRNA levels of lipogenic enzymes and proinflammatory cytokines. These changes were not observed in adipose tissue. In cultured hepatocytes, metformin increased AMPK phosphorylation and decreased fat deposition and inflammatory responses. In cultured macrophages, metformin partially blunted the stimulatory effects of lipopolysaccharide on JNK1 and nuclear factor kappa B p65 phosphorylation and cytokine expression. Thus, metformin protects against NAFLD largely through direct effects on decreasing hepatocyte fat deposition and on inhibiting inflammatory responses in both hepatocytes and macrophages.Grant Funding Source: Supported by ADA, AHA, NIH

Metformin Ameliorates Hepatic Steatosis and Inflammation without Altering Adipose Phenotype in Diet-Induced Obesity

Non-alcoholic fatty liver disease (NAFLD) is closely associated with obesity and insulin resistance. To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity. C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity-associated NAFLD and treated with metformin (150 mg/kg/d) orally for the last four weeks of HFD feeding. Compared with HFD-fed control mice, metformin-treated mice showed improvement in both glucose tolerance and insulin sensitivity. Also, metformin treatment caused a significant decrease in liver weight, but not adiposity. As indicated by histological changes, metformin treatment decreased hepatic steatosis, but not the size of adipocytes. In addition, metformin treatment caused an increase in the phosphorylation of liver AMP-activated protein kinase (AMPK), which was accompanied by an increase in the phosphorylation of liver acetyl-CoA carboxylase and decreases in the phosphorylation of liver c-Jun N-terminal kinase 1 (JNK1) and in the mRNA levels of lipogenic enzymes and proinflammatory cytokines. However, metformin treatment did not significantly alter adipose tissue AMPK phosphorylation and inflammatory responses. In cultured hepatocytes, metformin treatment increased AMPK phosphorylation and decreased fat deposition and inflammatory responses. Additionally, in bone marrow-derived macrophages, metformin treatment partially blunted the effects of lipopolysaccharide on inducing the phosphorylation of JNK1 and nuclear factor kappa B (NF-κB) p65 and on increasing the mRNA levels of proinflammatory cytokines. Taken together, these results suggest that metformin protects against obesity-associated NAFLD largely through direct effects on decreasing hepatocyte fat deposition and on inhibiting inflammatory responses in both hepatocytes and macrophages.

Hemin Improves Insulin Sensitivity in Skeletal Muscle in High Fat–Fed Mice

The present study examined whether hemin could prevent the development of high-fat diet-induced insulin resistance in the liver and skeletal muscle using a hyperinsulinemic-euglycemic clamp. A four-week high-fat feeding to mice increased the body weight, fat mass, and plasma levels of insulin and lipid, which were reduced by hemin. High-fat diet reduced whole body glucose uptake, which were increased by hemin. Insulin-stimulated hepatic glucose production (HGP) was increased by high-fat diet, but hemin had no significant effect on HGP. Skeletal muscle glucose uptake was reduced by high-fat diet, and hemin normalized the glucose uptake. High-fat diet increased triglyceride levels and mRNA levels of lipogenic enzymes, and decreased mRNA levels of enzymes involved in lipid β-oxidation, which was reversed by hemin. Phosphorylated AMP-activated protein kinase levels were increased in the skeletal muscle of high fat-fed hemin-injected mice. High-fat diet reduced mRNA levels of antioxidant enzymes and increased mRNA levels of inflammatory cytokines and nitrotyrosine levels, which was normalized by hemin in the skeletal muscle. However, hemin had no significant effect on these factors in the liver. These results suggest that hemin prevents the development of high-fat diet-induced insulin resistance by increased insulin sensitivity in the skeletal muscle.

Dietary lipoic acid-dependent changes in the activity and mRNA levels of hepatic lipogenic enzymes in rats

Effects of dietary alpha-lipoic acid on hepatic and serum lipid concentrations and the activity and mRNA levels of lipogenic enzymes were examined in rats. Rats were fed experimental diets containing varying amounts of lipoic acid (0, 1, 2.5, 5 g/kg) for 21 d. Lipoic acid profoundly decreased serum and liver concentrations of TAG, and also lowered serum concentrations of phospholipid and NEFA, and the concentration of cholesterol in the liver. A hypoglycaemic effect of this compound was also observed. Lipoic acid dose-dependently decreased the activity and mRNA levels of fatty acid synthase, ATP-citrate lyase, glucose 6-phosphate dehydrogenase, malic enzyme and pyruvate kinase in the liver despite that reductions were considerably attenuated in the NADPH-producing enzymes. This compound also dose-dependently lowered the mRNA levels of spot 14, adiponutrin, stearoyl-CoA desaturase 1, and Delta5- and Delta6-desaturases. In addition, lipoic acid dose-dependently lowered serum concentrations of insulin and leptin, but increased those of adiponectin. Lipoic acid appeared to reduce hepatic lipogenesis and hence decreases serum and liver lipid levels. Alterations in serum concentrations of insulin and (or) adiponectin may trigger this consequence.

Pharmacological Doses of Triiodothyronine Upregulate Lipogenic Enzyme Gene Expression in Rat White Adipose Tissue

Triiodothyronine (T (3)) is known to increase liver lipogenic enzyme gene expression both in vivo and in tissue culture. Conflicting results have been reported on the effect of T (3) on lipogenic enzyme gene expression in white adipose tissue. The results presented in this paper indicate that administration of pharmacological doses of T (3) in rats leads to increased fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), ATP-citrate lyase (ACL) and malic enzyme (ME) activity in white adipose tissue. The increase in lipogenic enzyme activity was associated with increased FAS, ACC, ACL and ME mRNA levels. The response was dose-dependent. Activity of lipogenic enzyme and the lipogenic enzyme mRNA levels were positively correlated to serum T (3) concentration. The in vivo effect of T (3) on lipogenic enzyme gene expression could be reproduced in primary white rat adipocyte culture. In conclusion, the results presented in this paper indicate that T (3) exerts a stimulatory effect on lipogenic enzyme gene expression in white adipose tissue both in vivo and in tissue culture. Significant effects of T (3) on lipogenic enzyme gene expression were only observed in the presence of relatively high (pharmacological) concentrations of the hormone.

Keratinocyte growth factor and the transcription factors C/EBP alpha, C/EBP delta, and SREBP-1c regulate fatty acid synthesis in alveolar type II cells.

Strategies to stimulate endogenous surfactant production require a detailed understanding of the regulation of lipogenesis in alveolar type II cells. We developed culture conditions in which keratinocyte growth factor (KGF) stimulates fatty acid and phospholipid synthesis. KGF stimulated acetate incorporation into phosphatidylcholine, disaturated phosphatidylcholine, and phosphatidylglycerol more than 5% rat serum alone. To determine the mRNA levels of lipogenic enzymes and transport proteins, we analyzed gene expression by oligonucleotide microarrays. KGF increased the mRNA levels for fatty acid synthase, stearoyl-CoA desaturase-1 (SCD-1), and epidermal fatty acid-binding protein more than rat serum alone. In addition, KGF increased the mRNA levels of the transcription factors CCAAT/enhancer-binding protein alpha (C/EBPalpha) and C/EBPdelta as well as SREBP-1c (ADD-1), but not PPARgamma. These changes in C/EBPalpha and C/EBPdelta were confirmed by in situ hybridization. SCD-1 was also found to be highly expressed in alveolar type II cells in vivo. Furthermore, KGF increased protein levels of fatty acid synthase, C/EBPalpha, C/EBPdelta, SREBP-1, epidermal fatty acid-binding protein, and SCD. Finally, the liver X receptor agonist T0901317 increased acetate incorporation and SREBP-1 but not SREBP-2 protein levels. In summary, KGF stimulates lipogenesis in type II cells by a coordinated expression of lipogenic enzymes and transport proteins regulated by C/EBP isoforms and SREBP-1c.

Hormonal and nutritional regulation of lipogenic enzyme mRNA levels in rat primary white and brown adipocytes.

Hyroid hormone stimulates hepatic lipogenesis in the rat by increasing the expression of relevant genes, including acetyl-CoA carboxylase and fatty acid synthase. S14 mRNA, which encodes a protein thought to be involved in lipogenesis, responds in parallel. The effects of thyroid hormone on lipogenesis in white and brown adipose tissue are less clear, and may be complicated by indirect effects of the hormone. Rat white and brown preadipocytes were therefore isolated, grown to confluence, and used to test direct effects of thyroid hormone, insulin, and glucose. Lipogenesis was assessed by tritiated water incorporation, and acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), and S14 mRNAs were measured by Northern analysis. Insulin (1 nM) increased lipogenesis about 9-fold in both white and brown adipocytes. Similar increases were seen in the levels of the three mRNAs. Thyroid hormone (1 microM) stimulated lipogenesis and acetyl-CoA carboxylase, fatty acid synthase, and S14 mRNA levels up to 2-fold in both types of adipocyte in the presence or absence of insulin. A high carbohydrate level (25 mM glucose) had no effect on lipogenesis compared to a low carbohydrate level (5 mM glucose) in white and brown adipocytes. There was no synergistic effect on lipogenesis by the combination of thyroid hormone and high carbohydrate level in both types of adipocytes. These experiments have shown that T3 has small, direct stimulatory effects on lipogenesis in adipocytes. These effects are seen at a pre-translational level, through the coordinate induction of ACC, FAS, and S14 mRNAs. Although lipogenic rates were usually higher in brown adipocytes than white adipocytes, very similar patterns of regulation were seen in the two cell types. These data support the idea that the divergent results seen concerning T3 regulation of the lipogenic pathway in both brown and white adipose tissue in vivo arise from secondary effects of the alteration of thyroid status.

Nutritional and hormonal regulation of mRNA levels of lipogenic enzymes in primary cultures of rat hepatocytes.

The effects of nutrients and hormones on the mRNA levels of acetyl-CoA carboxylase, fatty acid synthase, malic enzyme, and glucose 6-phosphate dehydrogenase were examined in primary cultures of rat hepatocytes during the process of induction. The addition of both glucose and insulin to the culture medium markedly enhanced the lipogenic enzyme mRNA induction due to either of them, in 16 h. Fructose or glycerol proved to be an effective substitute for glucose, suggesting that glycolytic metabolites were involved in the mRNA induction. It is remarkable that mRNA induction of acetyl-CoA carboxylase was the most sensitive to glucose and also to insulin among the lipogenic enzymes. Polyunsaturated fatty acids markedly reduced the mRNA induction of lipogenic enzymes. Dexamethasone enhanced all the lipogenic enzyme mRNA induction by insulin. On the other hand, triiodothyronine addition greatly increased the mRNA concentrations of lipogenic enzymes, but dexamethasone decreased rather than increased the mRNA induction by triiodothyronine. The effects of insulin on the induction of the lipogenic enzyme mRNAs were similar, but those of triiodothyronine were not. Triiodothyronine markedly enhanced malic enzyme mRNA induction by insulin with dexamethasone, and tended to enhance the induction of the acetyl-CoA carboxylase and fatty acid synthase mRNAs, but not that of glucose 6-phosphate dehydrogenase mRNA. It appeared that insulin and triiodothyronine synergistically enhanced lipogenic enzyme mRNA induction by glucose, but the mechanisms were different.

Hepatic and adipose tissue lipogenic enzyme mRNA levels are suppressed by high fat diets in the rat.

Small changes in lipogenic enzyme activity induced by dietary fats of different composition may, over the long term, have significant impact on the development of obesity. We have investigated the effect of high fat diets (45% of calories as fat) on abundance of mRNA encoding fatty acid synthetase (FAS) and glycerophosphate dehydrogenase (GPDH) in male Sprague-Dawley rats. When caloric intake was equal, the relative amount of hepatic FAS mRNA was greater in rats fed a saturated compared to a polyunsaturated fat diet. This difference could not be attributed to diet-induced changes in plasma insulin concentration. However, both fat diets suppressed hepatic FAS mRNA compared to a sucrose diet. Close correlation between FAS specific activity and the relative amount of mRNA suggested that regulation was mainly at a pre-translational level. Adipose tissue FAS mRNA was suppressed by the two fat diets equally while GPDH mRNA was unaffected by dietary composition. Retroperitoneal fat pads were significantly larger in rats fed saturated compared to those fed polyunsaturated fat for 26 weeks. We concluded that dietary saturated fats fail to suppress hepatic de novo lipogenesis as effectively as polyunsaturated fats, which may have implications for the prevention of obesity in humans.